Ekstraordinære indfrielser, Realkredit Danmark A/S
Lersø Parkallé 100
2100 København Ø
Telefon 7012 5300
Telefax 4514 9622
28. november 2022
Selskabsmeddelelse nummer 107/2022
Ekstraordinære indfrielser, Realkredit Danmark A/S
I medfør af lov om kapitalmarkeder §24 oplyses hermed om ekstraordinære indfrielser vedrørende Realkredit Danmark A/S pr. fredag den 25. november 2022. Oplysningerne fremgår af vedhæftede datafil.
Oplysningerne vil endvidere kunne ses på Realkredit Danmarks hjemmeside på www.rd.dk.
For yderligere informationer om dataformat og –indhold henvises til Nasdaq Copenhagen A/S’s hjemmeside.
Med venlig hilsen
Eventuel henvendelse kan rettes til chefanalytiker Hella Gebhardt Rønnebæk, 45 13 20 68.
Vedhæftede filerFor at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Graid Technology Announces Software Update Targeted at Enhancing Business Continuity for NVMe Deployments2.2.2023 15:00:00 CET | Press release
SupremeRAID™ new high availability feature provides an additional level of business continuity protection coupled with superior overall performance. SANTA CLARA, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Graid Technology, the award-winning data protection provider and developer of the only RAID card to offer customers access to the full performance of NVMe SSDs, is proud to announce its latest software release (V1.3) for SupremeRAID™ SR-1000 and SR-1010. The various enhancements in this release include features and software updates designed to support dual controller high availability along with support for multiple new NVMe SSDs. Among the enhanced features in the new release is a configurable strip size, allowing customers using RAID 0 and RAID 10 to realize even better server performance, a strategic move that continues to position SupremeRAID™ as the performance leader for both random and sequential workloads. "This latest release gives our customers peace of mind knowing that thei
Global Chauffeur Service Blacklane names Cindy Rubbens as Chief People Experience Officer and Gudrun Herrmann as Global Head of Communications2.2.2023 14:45:44 CET | Press release
Rubbens will oversee the continuous scaling of Blacklane while driving growth via learning and development, while Herrmann is tasked with building up an external and internal strategic communications function and co-drive its sustainability efforts. BERLIN, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Global chauffeur service, Blacklane, announced that it has named Cindy Rubbens Chief People Experience Officer (CPXO) and Gudrun Herrmann Global Head of Communications, effective immediately. Both will report to Blacklane CEO and CO-Founder Dr. Jens Wohltorf and will be charged with developing the Talent Attraction and Human Resources as well as Communications respectively during the company’s bid to scale while driving the next phase of growth. In her role as CPXO, Rubbens will support the sustainable development of Blacklane’s crew while the business continues scaling new, industry-leading services and expanding markets. Rubbens will focus on strengthening the Talent Attraction function while assi
Landsbankinn hf.: Financial results of Landsbankinn for 20222.2.2023 14:36:13 CET | Press release
Landsbankinn's net profit in 2022 was ISK 17.0 billion. There was good growth in loans to corporates, ISK 92.0 billion or the equivalent of 10%, having regard for currency changes.Mortgage loans grew by 59.0 billion with demand decreasing in the fourth quarter.ROE in the fourth quarter of 2022 was 8.2%, compared with 10.5% ROE in the same quarter of 2021. ROE in 2022 was 6.3%, despite solid core earnings. The negative impact reducing profitability was mainly a decrease in the fair value of the Bank’s holding in Eyrir Invest hf. The Bank’s target ROE is 10% at a minimum. Operating expenses are stable. Landsbankinn topped the Icelandic Performance Satisfaction Index for banking customers the fourth year in a row. The Bank’s market share in the retail market has never been higher and measures over 40% for the first time. Loans in arrears are at a historic low and loans in arrears were 0.2% at the turn of the year.In 2022, the Bank paid a dividend of ISK 20.5 billion and ISK 14.1 billion i
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference2.2.2023 14:00:00 CET | Press release
BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participate in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 8:00 a.m. ET. A webcast of the fireside chat, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. About Centessa Pharmaceuticals Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications. We operate with the conviction that
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa2.2.2023 14:00:00 CET | Press release
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody®sonelokimab in moderate-to-severe hidradenitis suppurativa Enrollment target of 210 patients randomized completed ahead of scheduleTop line results on the primary endpoint, for the novel IL-17A and IL-17F inhibitor Nanobody® sonelokimab, expected mid-2023First registered randomized trial in HS to use HiSCR75 as the primary endpoint; trial also includes adalimumab as an active reference armThe trial will proceed to its 24-week completion, including placebo patients re-randomized to sonelokimab and adalimumab patients switched to sonelokimab, with final read out expected, as planned, by Q4 2023 ZUG, Switzerland, February 2, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has completed enrollment of the target 210 pa